研究業績

ページタイトル画像

業績

免疫細胞治療

  • Suzuki S, Sakurai D, Sakurai T, Yonekura S, Iinuma T, Okuma Y, Ihara F, Arai T, Hanazawa T, Fukuda-Kawaguchi E, Ishii Y, Okamoto Y. Sublingual administration of liposomes enclosing alpha-galactosylceramide as an effective adjuvant of allergen immunotherapy in a murine model of allergic rhinitis. Allergol Int. S1323-8930(2019)
  • Harada K, Ihara F, Takami M, Kamata T, Mise N, Yoshizawa H, Hishiki T, Saito T, Terui K, Nakata M, Komatsu S, Ikeuchi T, Nakayama T, Yoshida H, and Motohashi, S. Soluble factors derived from neuroblastoma cell lines suppress dendritic cell differentiation and activation. Cancer Sci. 110(3):888-902 (2019).
  • Makita Y, Kunii N, Sakurai D, Ihara F, Motohashi S, Suzuki A, Nakayama T, and Okamoto Y. Activated iNKT cells enhance the anti-tumor effect of antigen specific CD8 T cells on mesothelin-expressing salivary gland cancer. BMC Cancer. 18(1):1254 (2018).
  • Takami M, Cunha C, Motohashi S, Nakayama T, and Iwashima M. TGF-β suppresses RasGRP1 expression and supports regulatory T cells resistance against p53-induced CD28-dependent T cell apoptosis.Eur. J. Immunol. 48(12):1938-1943 (2018).
  • Tanaka T, Kanesaka Y, Takami M, Suzuki A, Hosokawa H, Onodera A, Kamata T, Nagato K, Nakayama T, Yoshino I, and Motohashi, S. Role of Leukotriene B4 12-Hydroxydehydrogenase in α-Galactosylceramide-Pulsed Dendritic Cell Therapy for Non-Small Cell Lung Cancer. Biochem. Biophys. Res. Commun. 506(1):27-32 (2018).
  • Takami M, Iwashima M, and Motohashi S. Co-stimulatory Signaling Influences TGF-β-Dependent CD4+ T cell Differentiation and Its Plasticity. Chiba Survey Research Journal. 7(2):80-87 (2018).
  • Ihara F, Sakurai D, Yonekura S, Iinuma T, Yagi R, Sakurai T, Ito T, Matsuura A, Morimoto Y, Arai T, Suzuki S, Katayama K, Nakayama T, Okamoto Y. Identification of specifically reduced Th2 cell subsets in allergic rhinitis patients after sublingual immunotherapy. Allergy. 73(9):1823-1832 (2018).
  • Kimura MY, Igi A, Hayashizaki K, Mita Y, Shinzawa M, Kadakia T, Endo Y, Ogawa S, Yagi R, Motohashi S, Singer A, and Nakayama T. CD69 prevents PLZFhi innate precursors from prematurely exiting the thymus and aborting NKT2 cell differentiation. Nat. Commun. 9(1):3749 (2018).
  • Takami M, Ihara F, and Motohashi S. Clinical Application of iNKT Cell-mediated Anti-tumor Activity Against Lung Cancer and Head and Neck Cancer. Front. Immunol. 9:2021 (2018).
  • Mita Y, Kimura MY, Hayashizaki K, Koyama-Nasu R, Ito T, Motohashi S, Okamoto Y, and Nakayama T. Crucial role of CD69 in anti-tumor immunity through regulating the exhaustion of tumor-in ltrating T cells. Int. Immunol. 30(12):559-567 (2018).
  • Sakurai T, Yonekura S, Iinuma T, Sakurai D, Morimoto Y, Kaneko S, Okamoto Y. The Relationship of Pollen Dispersal with Allergy Symptoms and Immunotherapy: Allergen Immunotherapy Improves Symptoms in the Late Period of Japanese Cedar Pollen Dispersal. Int Arch Allergy Immunol. 177(3):245-254 (2018).
  • Sakurai D, Uchida R, Ihara F, Kunii N, Nakagawa T, Chazono H, Hanazawa T, Motohashi S, and Okamoto Y. Immunosuppressive property of submandibular lymph nodes in patients with head and neck tumors: differential distribution of regulatory T cells. BMC Res. Notes 11(1):479 (2018).
  • Hishiki T, Mise N, Harada K, Ihara F, Takami M, Saito T, Terui K, Nakata M, Komatsu S, Yoshida H, and Motohashi S. Invariant natural killer T infiltration in neuroblastoma with favorable outcome. Pediatr. Surg. Int. 34(2):195-201 (2018).
  • Hishiki T, Mise N, Harada K, Ihara F, Takami M, Saito T, Terui K, Nakata M, Komatsu S, Yoshida H, and Motohashi S. Frequency and proliferative response of circulating invariant natural killer T cells in pediatric patients with or without malignant solid tumors. Pediatr. Surg. Int. 34(2):169-176 (2018).
  • Kawashima T, Ikari N, Watanabe Y, Kubota Y, Motohashi S, Shimojo N, and Tsuji NM. Double-stranded RNA derived from lactic acid bacteria augments Th1 immunity via interferon-β from human dendritic cells. Front. Immunol. 9:27 (2018).
  • 櫻井大樹.頭頸部癌に対するNKT免疫細胞治療と今後の展開.耳鼻咽喉科免疫アレルギー、 35(4): 291-295, 2017.
  • Ihara F, Sakurai D, Horinaka A, Fujikawa A, Makita Y, Sakurai T, Yamasaki K, Kunii N, Motohashi S, Nakayama T, and Okamoto Y. CD45RA-Foxp3high regulatory T cells have a negative impact on the clinical outcome of head and neck squamous cell carcinoma. Cancer Immunol. Immunother. 66(10):1275-1285 (2017).
  • Kimura MY, Hayashizaki K, Tokoyoda K, Takamura S, Motohashi S, and Nakayama T. Crucial role for CD69 in allergic inflammatory responses: CD69-Myl9 system in the pathogenesis of airway inflammation. Immunol. Rev. 278(1):87-100 (2017).
  • Kamata T, Suzuki A, Mise N, Ihara F, Takami T, Makita Y, Horinaka A, Harada K, Kunii K, Yoshida S, Yoshino I, Nakayama T, and Motohashi S. Blockade of Programmed Death-1/Programmed Death Ligand pathway enhances the antitumor immunity of human invariant Natural Killer T cells. Cancer Immunol. Immunother. 65(12):1477-1489 (2016).
  • Hayashizaki K,* Kimura MY,* Tokoyoda K,* Hosokawa H, Shinoda K, Hirahara K, Ichikawa T, Onodera A, Hanazawa A, Iwamura C, Kakuta J, Muramoto K, Motohashi S, Tumes DJ, Iinuma T, Yamamoto H, Ikehara Y, Okamoto Y, and Nakayama T. Myosin light chain 9 and 12 are functional ligands for CD69 that regulate airway inflammation. (* Contributed equally) Sci. Immunol. 1(3): pp.eaaf9154 (2016).
  • Aoki T, Hino M, Koh K, Kyushiki M, Kishimoto H, Arakawa Y, Hanada R, Kawashima H, Kurihara J, Shimojo N, and Motohashi S. Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers. Pediatr. Blood Cancer 2016; 63(8):1461-4.
  • Hosokawa H, Tanaka T, Endo Y, Kato M, Shinoda K, Suzuki A, Motohashi S, Matsumoto M, Nakayama K I, and Nakayama T. Akt1-mediated Gata3 phosphorylation controls the repression of IFNγ in memory-type Th2 cells. Nat. Commun. 2016; 7:11289.
  • Mise N, Takami M, Suzuki A, Kamata T, Harada K, Hishiki T, Saito T, Terui K, Mitsunaga T, Nakata M, Ikeuchi T, Nakayama T, Yoshida H, and Motohashi S. Antibody-dependent cellular cytotoxicity toward neuroblastoma enhanced by activated invariant NKT cells. Cancer Sci. 2016; 107(3):233-241.
  • Horinaka A, Sakurai D, Ihara F, Makita Y, Kunii N, Motohashi S, Nakayama T, and Okamoto Y. Invariant NKT cells are resistant to circulating CD15+ myeloid-derived suppressor cells in patients with head and neck cancer. Cancer Sci. 2016; 107(3):207-216.
  • Hosokawa H, Kato M, Tohyama H, Tamaki Y, Endo Y, Kimura M Y., Tumes D J, Motohashi S, Matsumoto M, Nakayama K I, Tanaka T, and Nakayama T. Methylation of Gata3 at Arg261 regulates transactivation of the Il5 gene in T helper 2 cells. J. Biol. Chem. 2015; 290(21): 13095-13103.
  • Frigault M J, Lee J, Basil M, Carpenito C, Motohashi S, Scholler J, Kawalekar O U, Guedan S, McGettigan S, Posey A Jr, Ang S, Cooper L J, Platt J M, Johnson F B, Paulos C M, Zhao Y, Kalos M, Milone M C, and June C H. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol. Res. 2015; 3(4): 356-367.
  • Endo Y, Hirahara K, Iinuma T, Shinoda K, Tumes D J, Asou H K, Matsugae N, Obata-Ninomiya K, Yamamoto H, Motohashi S, Oboki K, Nakae S, Saito H, Okamoto Y, and Nakayama T. The Interleukin-33-p38 Kinase Axis Confers Memory T Helper 2 Cell Pathogenicity in the Airway. Immunity 2015; 42(2): 294-308.
  • Sun Y, Furihata T, Ishii S, Nagai M, Harada M, Shimozato O, Kamijo T, Motohashi S, Yoshino I, Kamiichi A, Kobayashi K, and Chiba K. Unique expression features of cancer-type organic anion transporting polypeptide 1B3 mRNA expression in human colon and lung cancers: potential biomarker implications. Clin. Transl. Med. 2014; 3: 37.
  • Watanabe Y, Onodera A, Kanai U, Ichikawa T, Obata-Ninomiya K, Wada T, Kiuchi M, Iwamura C, Tumes D J, Shinoda K, Yagi R, Motohashi S, Hirahara K, and Nakayama T. Trithorax complex component Menin controls differentiation and maintenance of T helper 17 cells. Proc. Natl. Acad. Sci. USA 2014; 111(35): 12829-12834.
  • Hamasaki S, Okamoto Y, Yonekura S, Okuma Y, Sakurai T, Iinuma T, Yamamoto H, Sakurai D, Horiguchi S, Yokota M.: Characteristics of the Chiba Environmental Challenge Chamber. Allergol Int.2014;63(1)41-50
  • Fujii S, Shimizu K, Okamoto Y, Kunii N, Nakayama T, Motohashi S, and Taniguchi M. NKT cells as an ideal anti-tumor immunotherapeutic. Front. Immunol. 2013;4:409
  • Hosokawa H, Tanaka T, Kato M, Shinoda K, Tohyama H, Hanazawa A, Tamaki Y, Hirahara K, Yagi R, Sakikawa I, Morita A, Nagira M, Poyurovsky, V. M, Suzuki Y, Motohashi S, and Nakayama T. Gata3/Ruvbl2 complex regulates T helper 2 cell proliferation via repression of Cdkn2c expression. Proc. Natl. Acad. Sci. USA. 2013;110(46):18626-18631.
  • Tumes D.J, Onodera A, Suzuki A, Shinoda K, Endo Y, Iwamura C, Hosokawa H, Koseki H, Tokoyoda K, Suzuki Y, Motohashi S, and Nakayama T. The polycomb protein Ezh2 regulates differentiation and plasticity of CD4+ T helper type-1 and type-2 cells. Immunity. 2013;39(5):819-832.
  • Okamoto Y, Ohta N, Okano M, Kamijo A, Gotoh M, Suzuki M, Takeno S, Terada T, Hanazawa T, Horiguchi S, Honda K, Matsune S, Yamada T, Yuta A, Nakayama T, Fujieda S. Guiding principles of subcutaneous immunotherapy for allergic rhinitis in Japan. Auris Nasus Larynx.2013;41:1-5.
  • Yonekura S, Okamoto Y, Yamamoto H, Sakurai T, Iinuma T, Sakurai D, Hanazawa T:Randomized double-blind study of prophylactic treatment with an antihistamine for seasonal allergic rhinitis. Int Arch Allergy Immunol 2013;162:71-8
  • Higaki T, Okano M, Kariya S, Fujiwara T, Haruna T, Hirai H, Murai A, Gotoh M, Okubo K, Yonekura S, Okamoto Y, Nishizaki K.:Determining minimal clinically important differences in Japanese cedar/cypress pollinosis patients.Allergol Int. 2013;62:487-93
  • Kinoshita T, Nohata N, Hanazawa T, Kikkawa N, Yamamoto N, Yoshino H, Itesako T, Enokida H, Nakagawa M, Okamoto Y, Seki N. Tumour-suppressive microRNA-29s inhibit cancer cell migration and invasion by targeting laminin-integrin signalling in head and neck squamous cell carcinoma. Br J Cancer. 2013 ;109:2636-45
  • Nohata N, Hanazawa T, Kinoshita T, Inamine A, Kikkawa N, Itesako T, Yoshino H, Enokida H, Nakagawa M, Okamoto Y, Seki N. Tumour-suppressive microRNA-874 contributes to cell proliferation through targeting of histone deacetylase 1 in head and neck squamous cell carcinoma. Br J Cancer. 2013 ;108:1648-58.
  • Kunii N, Zhao Y, Jiang S, Liu X, Scholler J, Balagopalan L, Samelson LE, Milone MC, and June CH. Enhanced function of redirected human T cells expressing linker for activation of T cells that is resistant to ubiquitylation. Hum Gene Ther. 2013 24(1):27-37
  • Nagato K, Motohashi S, Ishibashi F, Okita K, Yamasaki K, Moriya Y, Hoshino H, Yoshida S, Hanaoka H, Fuji S, Taniguchi M, Yoshino I, and Nakayama T. Accumulation of activated invariant natural killer T cells in the tumor microenvironment after α-Galactosylceramide-pulsed antigen presenting cells. J Clin.Immunol. 2012; 32: 1071-1081.
  • Iwamura C, Shinoda K, Endo Y, Watanabe Y, Tumes D.J, Motohashi S, Kawahara K, Kinjo Y, Nakayama T. Regulation of memory CD4 T-cell pool size and function by natural killer T cells in vivo. Proc Natl Acad Sci U S A. 2012; 109(42): 16992-16997
  • Kuwahara M, Yamashita M, Shinoda K, Tofukuji S, Onodera A, Shinnakasu R, Motohashi S, Hosokawa H, Tumes D, Iwamura C, Lefebvre V, and Nakayama T. The transcription factor Sox4 is a downstream target of TGF-β signaling and suppresses GATA3-induced TH2 cell differentiation. Nat. Immunol. 2012; 13(8): 778-786
  • Nagai M, Furihata T, Matsumoto S, Ishii S, Motohashi S, Yoshino I, Ugajin M, Miyajima A, Matsumoto S, and Chiba K. Identification of a new organic anion transporting polypeptide 1B3 mRNA isoform primarily expressed in human cancerous tissues and cells. Biochem Biophys Res Commun. 2012; 418(4): 818-823
  • Yamashita J, Iwamura C, Mitsumori K, Hosokawa H, Sasaki T, Takahashi M, Tanaka H, Kaneko K, Hanazawa A, Watanabe Y, Shinoda K, Tumes D, Motohashi S, Nakayama T. Murine Schnurri-2 controls Natural Killer cell function and lymphoma development. Leuk. Lymphoma. 2012; 53(3): 479-486
  • Kitajima M, Ito T, Tumes DJ, Endo Y, Onodera A, Hashimoto K, Motohashi S, Yamashita M, Nishimura T, Ziegler SF, Nakayama T. Memory type 2 helper T cells induce long-lasting antitumor immunity by activating natural killer cells. Cancer Res. 2011; 71(14): 4790-4798.
  • Motohashi S, Okamoto Y, and Nakayama T. Clinical trials of invariant Natural Killer T cell-based immunotherapy for cancer. In the book "Natural killer T cells. : setting the balance in the regulation of tumor immunity". Edited by Berzofsky and Terabe. 2011; 185-198.
  • Kurosaki M, Horiguchi S, Yamasaki K, Uchida Y, Motohashi S, Nakayama T, Sugimoto A, and Okamoto Y. Migration and immunological reaction after the administration of αGalCer-pulsed antigen-presenting cells into the submucosa of patients with head and neck cancer. Cancer Immunol. Immunother. 2011; 60(2): 207-215.
  • Motohashi S, Okamoto Y, Yoshino I, and Nakayama T. Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer. Clin Immunol. 2011; 140(2):167-176.
  • Yamasaki K, Horiguchi S, Kurosaki M, Kunii N, Nagato K, Hanaoka H, Shimizu N, Ueno N, Yamamoto S, Taniguchi M, Motohashi S, Nakayama T, and Okamoto Y. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy. Clin. Immunol. 2011; 138(3): 255-265.
  • Okita K, Motohashi S, Shinnakasu R, Nagato K, Yamasaki K, Sato Y, Kitamura H, Hijikata A, Yamashita M, Shimizu K, Fujii S, Ohara O, Taniguchi M, Sakaida I, and Nakayama T. A set of genes associated with the interferon-γ response of lung cancer patients undergoing α-galactosylceramide-pulsed dendritic cell therapy. Cancer Sci. 2010; 101 (11): 2333-2340.
  • Ishii Y, Motohashi S, Shimizu K, Nakayama T, Taniguchi M, and Fujii S. Application of NKT cells in immunotherapy. Curr Immunol Rev. 2010; 6: 109-115.
  • Fujii S, Motohashi S, Shimizu K, Nakayama T, Yoshiga Y, and Taniguchi M. Adjuvant activity mediated by iNKT cells. Semin Immunol. 2010; 22 (2): 97-102.
  • Suzuki M, Wada H, Yoshino M, Tian L, Shigematsu H, Suzuki H, Alaa M, Tamura H, Fujiwara T, Nagato K, Motohashi S, Moriya Y, Hoshino H, Yoshida S, Shibuya K, Hiroshima K, Nakatani Y, and Yoshino I. Molecular Characterization of Chronic Obstructive Pulmonary Disease-Related Non-Small Cell Lung Cancer Through Aberrant Methylation and Alterations of EGFR Signaling. Ann Surg Oncol. 2010; 17 (3): 878-888.
  • Alaa M, Suzuki M, Yoshino M, Tian L, Suzuki H, Nagato K, Fujiwara T, Wada H, Moriya Y, Hoshino H, Motohashi S, Yoshida S, Shibuya K, Hiroshima K, Nakatani Y. Abdrabou A, Elkholy M, Mahfouz T, and Yoshino I. Prostaglandin E2 receptor 2 overexpression in squamous cell carcinoma of the lung correlates with p16INK4A methylation and an unfavorable prognosis. Int J Oncol. 2009; 34 (3): 805-812.
  • Kitajima M, Iwamura C, Miki H T, Shinoda K, Endo Y, Watanabe Y, Shinnakasu R, Hosokawa H, Hashimoto K, Motohashi S, Koseki H, Ohara O, Yamashita M, and Nakayama T. Enhanced Th2 cell differentiation and allergen-induced airway inflammation in Zfp35-deficient mice. J Immunol. 2009; 183 (8): 5388-5396.
  • Kunii N, Horiguchi S, Motohashi S, Yamamoto H, Ueno N, Yamamoto S, Sakurai D, Taniguchi M, Nakayama T, and Okamoto Y. Combination therapy of in vitro-expanded natural killer T cells and α-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci. 2009; 100 (6): 1092-1098.
  • Miki H T, Hasegawa A, Iwamura C, Shinoda K, Tofukuji S, Watanabe Y, Hosokawa H, Motohashi S, Hashimoto K, Shirai M, Yamashita M, and Nakayama T. CD69 controls the pathogenesis of allergic airway inflammation. J Immunol. 2009; 183 (12): 8203-8215.
  • Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K, Hanaoka H, Shimizu N, Suzuki M, Yoshino I, Taniguchi M, Fujisawa T, and Nakayama T. A phase I-II study of α-Galactosylceramide(KRN7000)-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol. 2009; 182 (4): 2492-2501.
  • Motohashi S, and Nakayama T. Invariant natural killer T cell-based immunotherapy for cancer. Immunotherapy. 2009; 1 (1): 73-82.
  • Motohashi S, and Nakayama T. Natural killer T cell-mediated immunotherapy for malignant diseases. Frontiers in Bioscience. 2009; 1(1): 108-116.
  • Ito T, Hasegawa A, Hosokawa H, Yamashita M, Motohashi S, Naka T, Okamoto Y, Fujita Y, Ishii Y, Taniguchi M, Yano I, and Nakayama T. Human Th1 differentiation induced by lipoarabinomannan / lipomannon from Mycobacterium bovis BCG Tokyo-172. International Immunology. 2008; 20 (7): 849-860.
  • Shinnakasu R, Yamashita M, Kuwahara M, Hosokawa H, Hasegawa A, Motohashi S, and Nakayama T. Gfi1-mediated stabilization of GATA3 protein is required for Th2 cell differentiation. J Biol Chem. 2008; 283(42): 28216-28225.
  • Suzuki M, Mohamed S, Nakajima T, Kubo R, Tian L, Fujiwara T, Suzuki H, Nagato K, Chiyo M, Motohashi S, Yasufuku K, Iyoda A, Yoshida S, Sekine Y, Shibuya K, Hiroshima K, Nakatani Y, Yoshino I, and Fujisawa T. Aberrant methylation of CXCL12 in non-small cell lung cancer is associated with an unfavorable prognosis. Int J Oncol. 2008; 33 (1): 113-119.
  • Yamashita M, Kuwahara M, Suzuki A, Hirahara K, Shinnakasu R, Hosokawa H, Hasegawa A, Motohashi S, Iwama A, and Nakayama T. Bmi1 regulates memory CD4 T cell survival via repression of the Noxa gene. J Exp Med. 2008; 205 (5): 1109-1120.

酵素補充療法

血管新生治療

臨床試験部